HLB Co., Ltd.
028300
株式のランク
#4100
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
株価
$29.70
時価総額
$3.95B
変化（1日）
0.47%
変化（1年）
2.42%
国
KR
取引 HLB Co., Ltd. (028300)
カテゴリー
Healthcare
HLB Co., Ltd.（028300）のEPS
June 2026 時点のEPS TTM: $-1.12
HLB Co., Ltd.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-1.12です。2023年末には、EPSは$-1.20で、2022年のEPS$-0.55と増加でした。
HLB Co., Ltd.のEPS履歴（2012から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-1.12 | 132.67% |
| 2024 | $-0.48 | -60.27% |
| 2023 | $-1.20 | 119.01% |
| 2022 | $-0.55 | -19.90% |
| 2021 | $-0.69 | 15.14% |
| 2020 | $-0.60 | 57.18% |
| 2019 | $-0.38 | -259.25% |
| 2018 | $0.24 | -240.42% |
| 2017 | $-0.17 | 40.25% |
| 2016 | $-0.12 | -194.53% |
| 2015 | $0.13 | -689.86% |
| 2014 | $-0.02 | -80.40% |
| 2013 | $-0.11 | 8.00% |
| 2012 | $-0.10 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -1,650.86% |
US
|
|
| $-7.98 | 614.54% |
US
|
|
| $-5.29 | 373.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,583.88% |
NL
|
